If you have been reading about reference standard and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-07. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
== History == Efficacy was evaluated in HERIZON-BTC-01 (NCT04466891), an open-label multicenter, single-arm trial in 62 participants with unresectable or metastatic HER2-positive (IHC3+) biliary tract cancer. Participants were required to have received at least one prior gemcitabine-containing regimen in the advanced disease setting. The US Food and Drug Administration (FDA) granted the application for zanidatamab priority review, breakthrough therapy, and orphan drug designations.
During the War against the Peru-Bolivian Confederation, relations between the Peru-Bolivian Confederation and the Argentine Confederation had deteriorated, among other reasons due to Bolivian President Andrés de Santa Cruz's support for unitary groups that had carried out at least four incursions since the southern Bolivia to the northern Argentine provinces in the years before the war. This led to anti-Peruvian measures on the part of the Argentine Government, such as that of February 13, 1837, where Rosas declared closed all commercial, epistolary and any kind of communication between the inhabitants of the Argentine Confederation and those of Peru and Bolivia, declaring " traitor to the country" to anyone who crossed the border into those countries. Both confederations did not have formal diplomatic relations, so the declaration was intended to externalize the break in relations between the two countries. Although Juan Manuel de Rosas was not anti-Peruvian, since he would declare war on Santa Cruz and his supporters, but not on the Peruvian states, it can be considered an episode of anti-Peruvianism in the history of Argentina, since the concern that the federal caudillo would have, in front of the power that Peru would be obtaining, in the Manifiesto de las razones que legitiman la Declaración de Guerra contra el gobierno del General Santa Cruz, Titulado Protector de la Confederación Perú-Boliviana [Manifesto of the reasons that legitimize the Declaration of War against the government of General Santa Cruz, Entitled Protector of the Peru-Bolivian Confederation].
==== Analysis ==== Analysis of FISH specimens is done by fluorescence microscopy by a clinical laboratory specialist in cytogenetics. For oncology, generally, a large number of interphase cells are scored in order to rule out low-level residual disease, generally between 200 and 1,000 cells are counted and scored. For congenital problems usually 20 metaphase cells are scored.
Klaus H. Hofmann (February 21, 1911 – December 25, 1995) was an American biological chemist and medical researcher. The New York Times called Hofmann an "expert on synthesis of body compounds". His career was highlighted by synthesis of a prototype birth control pill, isolation and structural characterization of biotin (vitamin H), determination of the lysine specificity of the pancreatic protease trypsin (an attribute that made it the enzyme of first choice in protein sequence determinations), the first chemical synthesis of a fully biologically-active portion of the peptide hormone (adrenocorticotopic hormone - ACTH), and structure-function studies on ribonuclease (RNase).
Sources: en.wikipedia.org
=== Penicillin V === Penicillin V can be taken by mouth because it is relatively resistant to stomach acid. Doses higher than 500 mg are not fully effective because of poor absorption. It is used for the same bacterial infections as those of penicillin G and is the most widely used form of penicillin. However, it is not used for diseases, such as endocarditis, where high blood levels of penicillin are required.
==== Adoption tax credit ==== The law changes the existing nonrefundable tax credit for up to $17,280 of qualified adoption expenses. As of January 1, 2025, up to $5,000 of the adoption tax credit is a refundable tax credit.
In March 2020, the release of 15.ai, a free web application created by an anonymous MIT researcher that could generate convincing character voices using minimal training data, was one of the earliest publicly available uses for generative AI. The platform is credited as the first mainstream service for audio deepfakes. In 2021, DALL-E, a closed-source transformer-based generative model developed by OpenAI, drew widespread attention to text-to-image generation. Other projects, including open-source approaches such as VQGAN+CLIP and DALL·E Mini (later renamed Craiyon), made similar systems more accessible to the public. Dream by Wombo was released at the end of 2021, followed by the releases of Midjourney and Stable Diffusion in 2022. In November 2022, ChatGPT was released to the public. By 2023, it popularized generative AI for general-purpose text-based tasks.
Sources: en.wikipedia.org
During the tenure of the Marquess of Carnarvon as the Grand Master of the Premier Grand Lodge of England in 1754, nine Provincial Grand Masters were appointed to oversee the development of Ancient Freemasonry in their nine respective Provincial Grand Lodges. Cuba was listed as one of these nine Grand Lodges, alongside South Carolina, South Wales, Antigua, North America, Barbados, Sicily, Germany, and Chester. This indicates to some Masonic historians that Freemasonry had already made it to the island by this point, but in what numbers is unknown. The first known Lodge in Cuba arrived with the British occupation of Havana in 1762, during the Anglo-Spanish War. It was common practice in this era for the Grand Lodges in the British Isles to establish Military Lodges in foreign locales, as they had already done in Jamaica. The 48th Regiment of Foot, known more commonly at the time as Webb's Regiment or the D. Webb Regiment under the command of Colonel Daniel Webb and Lieutenant Colonel Christopher Teesdale, landed in Cuba with the 2nd Brigade under Brigadier General Walsh and the Earl of Albemarle's invasion force. After landing in Cuba, the 48th joined with the rest of the brigade to attack and occupy Havana. The Military Lodge connected to the 48th Regiment of Foot held a warrant from the Grand Lodge of Ireland as Lodge No. 218, chartered in 1750. While the Regiment was stationed here in Havana, it quartered its officers in the Convent of San Francisco, where the earliest Masons in Cuba had been involved in its construction a half-century earlier.
== World Accreditation Day (WAD) == NABL celebrates World Accreditation Day (WAD) every year on 9 June. World accreditation day is celebrated to provide awareness on accreditation and how accreditation benefits its stakeholders.
==== Low sex hormone levels ==== Clinical studies have consistently associated medical and recreational opioid use with hypogonadism (low sex hormone levels) in different sexes. The effect is dose-dependent. Most studies suggest that the majority (perhaps as much as 90%) of chronic opioid users develop hypogonadism. A 2015 systematic review and meta-analysis found that opioid therapy suppressed testosterone levels in men by about 165 ng/dL (5.7 nmol/L) on average, which was a reduction in testosterone level of almost 50%. Conversely, opioid therapy did not significantly affect testosterone levels in women. However, opioids can also interfere with menstruation in women by limiting the production of luteinizing hormone (LH). Opioid-induced hypogonadism likely causes the strong association of opioid use with osteoporosis and bone fracture, due to deficiency in estradiol. It also may increase pain and thereby interfere with the intended clinical effect of opioid treatment. Opioid-induced hypogonadism is likely caused by their agonism of opioid receptors in the hypothalamus and the pituitary gland. One study found that the depressed testosterone levels of heroin addicts returned to normal within one month of abstinence, suggesting that the effect is readily reversible and is not permanent. As of 2013, the effect of low-dose or acute opioid use on the endocrine system is unclear. Long-term use of opioids can affect the other hormonal systems as well.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.